BR0306685A - Composição farmacêutica contendo grelina - Google Patents
Composição farmacêutica contendo grelinaInfo
- Publication number
- BR0306685A BR0306685A BR0306685-1A BR0306685A BR0306685A BR 0306685 A BR0306685 A BR 0306685A BR 0306685 A BR0306685 A BR 0306685A BR 0306685 A BR0306685 A BR 0306685A
- Authority
- BR
- Brazil
- Prior art keywords
- buffer
- pharmaceutical composition
- ghrelin
- phosphate
- composition containing
- Prior art date
Links
- 101800001586 Ghrelin Proteins 0.000 title abstract 4
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000012004 Ghrelin Human genes 0.000 title 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 5
- 239000000872 buffer Substances 0.000 abstract 5
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 2
- 102000000393 Ghrelin Receptors Human genes 0.000 abstract 2
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 abstract 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 abstract 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- PFTCBBOADJQVTP-UHFFFAOYSA-N acetic acid;boric acid;phosphoric acid Chemical compound CC(O)=O.OB(O)O.OP(O)(O)=O PFTCBBOADJQVTP-UHFFFAOYSA-N 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 229960001269 glycine hydrochloride Drugs 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002146155 | 2002-05-21 | ||
PCT/JP2003/006349 WO2003097083A1 (fr) | 2002-05-21 | 2003-05-21 | Compositions medicinales contenant de la ghreline |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0306685A true BR0306685A (pt) | 2005-04-26 |
Family
ID=29545111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0306685-1A BR0306685A (pt) | 2002-05-21 | 2003-05-21 | Composição farmacêutica contendo grelina |
Country Status (11)
Country | Link |
---|---|
US (3) | US20060166871A1 (pt) |
EP (1) | EP1506786B1 (pt) |
JP (1) | JP5000848B2 (pt) |
KR (1) | KR20050012224A (pt) |
CN (1) | CN100411683C (pt) |
AU (1) | AU2003235401B2 (pt) |
BR (1) | BR0306685A (pt) |
CA (1) | CA2471879C (pt) |
ES (1) | ES2615484T3 (pt) |
IL (2) | IL162796A0 (pt) |
WO (1) | WO2003097083A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2383796T3 (es) | 2001-12-18 | 2012-06-26 | Alizé Pharma SAS | Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina |
US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
WO2003097083A1 (fr) | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Compositions medicinales contenant de la ghreline |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
CA2543507C (en) * | 2003-10-24 | 2012-05-01 | Theratechnologies Inc. | Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions |
CN1321131C (zh) * | 2003-12-26 | 2007-06-13 | 李宁 | 猪Ghrelin衍生物及其编码基因与应用 |
CA2566703A1 (en) * | 2004-05-11 | 2005-11-24 | Vishwa Deep Dixit | Methods of inhibiting proinflammatory cytokine expression using ghrelin |
AU2005277389A1 (en) * | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
CN101022822B (zh) * | 2004-08-24 | 2012-06-27 | 第一三共株式会社 | 生理学活性肽的液体制剂 |
EP1814591A4 (en) * | 2004-11-22 | 2009-04-22 | Anadis Ltd | BIOACTIVE PREPARATIONS |
WO2006112443A1 (ja) * | 2005-04-15 | 2006-10-26 | Shinshu University | トリアセチンの新規な利用方法及び超音波診断の検査補助剤 |
EP2264162A1 (en) * | 2005-07-02 | 2010-12-22 | Arecor Limited | Stable aqueous systems comprising proteins |
RU2420306C2 (ru) * | 2005-11-21 | 2011-06-10 | Юниверсити Оф Миязаки | ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ДЛЯ УСКОРЕННОГО ЗАЖИВЛЕНИЯ КОЖИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ГРЕЛИН И ЕГО ПРОИЗВОДНЫЕ ИЛИ ВЕЩЕСТВО, ВОЗДЕЙСТВУЮЩЕЕ НА РЕЦЕПТОР GHS-R1a |
US20090053334A1 (en) | 2006-01-31 | 2009-02-26 | Nat. Uni. Corp. Hokkaido University | Ghrelin production promoter |
EP2012809B1 (en) | 2006-03-10 | 2013-05-22 | Ipsen Pharma | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
US7763707B2 (en) | 2006-03-13 | 2010-07-27 | Liat Mintz | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation |
RU2470940C2 (ru) * | 2006-03-13 | 2012-12-27 | Лиат МИНТЦ | Применение варианта сплайсинга грелина для лечения кахексии, и/или анорексии, и/или анорексии-кахексии, и/или нарушения питания, и/или липодистрофии, и/или мышечного истощения, и/или стимуляции аппетита |
EP2083842B1 (en) * | 2006-09-27 | 2013-08-28 | Ipsen Pharma S.A.S. | Analogs of ghrelin substituted at the n-terminal |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
JP5485876B2 (ja) | 2007-05-31 | 2014-05-07 | アリゼ ファーマ エスアーエス | 代謝疾患の治療における治療剤としての非アシル化グレリン |
WO2009039979A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
CA2726824A1 (en) | 2008-05-01 | 2009-11-05 | Arecor Limited | Protein formulation |
US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
EP2328607A1 (en) | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
EP3196210A1 (en) | 2011-11-23 | 2017-07-26 | Amgen, Inc | Methods of treatment using an antibody against interferon gamma |
ES2705499T3 (es) | 2011-12-15 | 2019-03-25 | Millendo Therapeutics Sas | Fragmentos de ghrelina no acilada para usar en el tratamiento del síndrome de Prader-Willi |
JP2015510505A (ja) * | 2012-02-03 | 2015-04-09 | ジーランド ファーマ アクティーゼルスカブ | グレリン類似体 |
FR2987268B1 (fr) * | 2012-02-28 | 2014-07-11 | Ammtek | Formulations liquides de sulfamides hypoglycemiants |
WO2015017123A1 (en) | 2013-07-16 | 2015-02-05 | Liat Mintz | Ghrelin splice variant for treating neuronal damage,neurodegenerative disease, parkinsons disease, alzheimers disease, and/or depression |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
EP3191111A4 (en) * | 2014-09-09 | 2018-06-13 | The Feinstein Institute for Medical Research | Treatment of radiation injury using ghrelin |
CA2962630C (en) | 2014-09-27 | 2023-02-21 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition for injection |
US20180296647A1 (en) * | 2015-10-14 | 2018-10-18 | Kurume University | Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
JP2018169273A (ja) * | 2017-03-29 | 2018-11-01 | 東ソー株式会社 | ペプチドの吸着抑制剤 |
KR20210027409A (ko) * | 2018-07-03 | 2021-03-10 | 페넥 파마슈티컬스, 인크. | 무수 싸이오황산나트륨 및 이의 제형 |
EP3965795A4 (en) * | 2019-05-07 | 2022-06-01 | Frontier Biotechnologies Inc. | STABLE ALBUVIRTID COMPOSITIONS |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651637B2 (ja) * | 1985-03-28 | 1994-07-06 | エーザイ株式会社 | ペプタイドの吸着防止組成物 |
JPS62238298A (ja) * | 1986-04-08 | 1987-10-19 | Sanraku Inc | 新規アントラサイクリン抗生物質dcp−1及び2 |
JPH0669956B2 (ja) * | 1988-09-30 | 1994-09-07 | 旭化成工業株式会社 | ポリペプタイド類の吸着防止剤 |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
SE9300105D0 (sv) | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | Stable protein solution |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
DE4340781C3 (de) | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
US5780431A (en) | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
US5998381A (en) * | 1996-12-06 | 1999-12-07 | Ophidian Pharmaceuticals, Inc. | Compounds that bind bacterial pili |
BR9913857A (pt) | 1998-09-17 | 2001-06-12 | Lilly Co Eli | Formulações de proteìna |
ATE449174T1 (de) * | 1999-07-23 | 2009-12-15 | Kenji Kangawa | Neue peptide |
WO2001087335A2 (en) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
WO2001087322A2 (en) | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
EP1301200A2 (en) | 2000-05-19 | 2003-04-16 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
CA2411667A1 (en) * | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
ATE382057T1 (de) | 2001-06-28 | 2008-01-15 | Novo Nordisk As | Stabile formulierung von modifiziertem glp-1 |
WO2003084983A1 (fr) * | 2002-04-11 | 2003-10-16 | Daiichi Suntory Pharma Co., Ltd. | Procede de production d'un peptide modifie |
WO2003097083A1 (fr) | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Compositions medicinales contenant de la ghreline |
-
2003
- 2003-05-21 WO PCT/JP2003/006349 patent/WO2003097083A1/ja active Application Filing
- 2003-05-21 KR KR10-2004-7010362A patent/KR20050012224A/ko not_active Application Discontinuation
- 2003-05-21 EP EP03752939.3A patent/EP1506786B1/en not_active Expired - Lifetime
- 2003-05-21 US US10/500,561 patent/US20060166871A1/en not_active Abandoned
- 2003-05-21 CN CNB038028301A patent/CN100411683C/zh not_active Expired - Lifetime
- 2003-05-21 ES ES03752939.3T patent/ES2615484T3/es not_active Expired - Lifetime
- 2003-05-21 IL IL16279603A patent/IL162796A0/xx active IP Right Grant
- 2003-05-21 JP JP2004505079A patent/JP5000848B2/ja not_active Expired - Lifetime
- 2003-05-21 BR BR0306685-1A patent/BR0306685A/pt not_active IP Right Cessation
- 2003-05-21 AU AU2003235401A patent/AU2003235401B2/en not_active Expired
- 2003-05-21 CA CA2471879A patent/CA2471879C/en not_active Expired - Lifetime
-
2004
- 2004-06-30 IL IL162796A patent/IL162796A/en unknown
-
2007
- 2007-07-25 US US11/878,532 patent/US8440628B2/en not_active Expired - Lifetime
-
2012
- 2012-03-06 US US13/413,581 patent/US8518893B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPWO2003097083A1 (ja) | 2005-10-06 |
EP1506786A1 (en) | 2005-02-16 |
ES2615484T3 (es) | 2017-06-07 |
US8440628B2 (en) | 2013-05-14 |
JP5000848B2 (ja) | 2012-08-15 |
AU2003235401A1 (en) | 2003-12-02 |
IL162796A0 (en) | 2005-11-20 |
WO2003097083A1 (fr) | 2003-11-27 |
US20120264691A1 (en) | 2012-10-18 |
CA2471879C (en) | 2014-02-25 |
CN100411683C (zh) | 2008-08-20 |
KR20050012224A (ko) | 2005-01-31 |
US20060166871A1 (en) | 2006-07-27 |
AU2003235401B2 (en) | 2008-09-25 |
EP1506786B1 (en) | 2016-11-23 |
IL162796A (en) | 2011-01-31 |
CA2471879A1 (en) | 2003-11-27 |
US20080081787A1 (en) | 2008-04-03 |
EP1506786A4 (en) | 2009-07-29 |
CN1622822A (zh) | 2005-06-01 |
US8518893B2 (en) | 2013-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0306685A (pt) | Composição farmacêutica contendo grelina | |
ES2291264T3 (es) | Formulacion farmaceutica estabilizada comprendiendo una hormona de crecimiento e histidina. | |
BR0300826A (pt) | Formulação antitumor com base em paclitaxel melhorada | |
US5026825A (en) | Intranasal calcitonin formulations | |
CA2672902A1 (en) | Formulations | |
TR200801968T2 (tr) | HFSH sulu formülasyon. | |
EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
DK1044015T3 (da) | Formuleringer med amylinagonistpeptider og insulin | |
AR040529A1 (es) | Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol | |
CY1113834T1 (el) | Υγρο παρασκευασμα αυξητικης ορμονης | |
ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
KR880013572A (ko) | 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 | |
WO2003086324A3 (en) | Preparation and use of a stable formulation of allosteric effector compounds | |
CA2477557A1 (en) | Stabilized albumin preparations | |
ES2283446T3 (es) | Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal. | |
TR200002543T2 (tr) | Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar | |
KR950024769A (ko) | 고농도 tcf 제제 | |
BR9803730A (pt) | Preparados farmacêuticos de cilansetron estabilizados contra a racemização. | |
DK1153615T3 (da) | Farmaceutisk formulering til intravenøs eller intramuskulær octreotid-indgivelse | |
KR880002507A (ko) | 페닐퀴놀린 카복실산의 동결건조 약제 조성물 | |
ATE359059T1 (de) | Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp- antagonisten | |
DE60034149D1 (de) | Hydrophobe aminosäuren enthaltende trockene zusammensetzung | |
ES2222975T3 (es) | Uso de antagonistas de pirimidina endotelina en animales de compañia. | |
DE60141632D1 (de) | Zusammensetzung zur stabilisierung von fettlöslichen vitaminen in wässeriger lösung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI ASUBIO PHARMA CO., LT Free format text: ALTERADO DE: DAIICHI SUNTORY PHARMA CO., LTD. |
|
B25G | Requested change of headquarter approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI ASUBIO PHARMA CO., LT Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDA ATRAVES DA PETICAO NO 020050150101/RJ DE 20/12/2005. |
|
B25D | Requested change of name of applicant approved |
Owner name: KENJI KANGAWA (JP) , ASUBIO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAIICHI ASUBIO PHARMA CO., LTD. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: KENJI KANGAWA (JP) , ASUBIO PHARMA CO., LTD. (JP) Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020100090868/RJ DE 28/09/2010, APRESENTE O DOCUMENTO DE FUSAO COM A DEVIDA LEGALIZACAO CONSULAR. |
|
B25A | Requested transfer of rights approved |
Owner name: KENJI KANGAWA (JP) , DAIICHI SANKYO COMPANY, LIMIT Free format text: TRANSFERIDO POR FUSAO DE: ASUBIO PHARMA CO., LTD. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |